Bulk data import and seamless IRS e-filing with efile direct, add-on feature help employers complete 1095-C and 1094-C forms on time and avoid penalties. REDMONDBulk data import and seamless IRS e-filing with efile direct, add-on feature help employers complete 1095-C and 1094-C forms on time and avoid penalties. REDMOND

ACA March Deadline Nears: ez1095 XML Import and New Direct E-File Add-On Deliver Fast, Compliant Filing

2026/02/27 20:30
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Bulk data import and seamless IRS e-filing with efile direct, add-on feature help employers complete 1095-C and 1094-C forms on time and avoid penalties.

REDMOND, Wash., Feb. 27, 2026 /PRNewswire/ — With the ACA electronic filing deadline in March fast approaching, Halfpricesoft.com is urging employers, HR professionals, and ACA filing specialists to act now using ez1095, featuring its time-saving XML import capability and the new direct e-file add-on for faster submission to the IRS. This powerful combination allows users to import employee data in bulk, prepare Forms 1095-C and 1094-C with greater accuracy, and transmit filings electronically from within the software, reducing manual steps and helping organizations meet critical compliance deadlines.

Employers and ACA filing professionals should begin processing now to avoid penalties and last-minute delays. Download ez1095 today, add the direct e-file feature, and complete your ACA filings before the March deadline visit here to get started.Costs start at $295.00 for the paper print version (efile and efile add-on feature additional costs).

“ACA compliance demands speed and accuracy as the March deadline nears,” said Dr. Ge, Founder of Halfpricesoft.com. “With direct e-file and XML import, ez1095 lets employers prepare, file, and meet IRS requirements on time.”

Why Immediate ACA Processing Is Critical: Organizations that delay ACA reporting risk IRS penalties, employee form distribution issues, and last-minute filing stress. The enhanced ez1095 solution accelerates the entire workflow, from data import to final submission, makes it ideal for high-volume filers and businesses working against the clock.

News for 2026 ACA Filers:

  • Direct IRS e-file add-on for transmitting ACA forms from within ez1095
  • Bulk XML import to dramatically reduce manual data entry
  • Faster end-to-end processing for time-sensitive March deadlines
  • Improved accuracy with fewer data handling steps

Key Features of ez1095:

  • Complete preparation of Forms 1095-C and 1094-C
  • Paper printing and PDF generation for employee distribution
  • Step-by-step interface for easy setup and processing
  • Designed for mid-size and large employers and ACA professionals
  • Handles high-volume employee data with ease
  • Affordable one-time pricing with no recurring monthly fees
  • Free instructional guides and extended, live customer support

A Complete ACA Workflow in One Solution: By combining bulk data import with direct electronic filing, ez1095 eliminates the need for multiple systems and reduces the risk of errors caused by manual transfers, saving valuable time for HR teams, payroll departments, and accounting firms. Prices for efile start at $495.00 for Federal (self-filing), $695.00 for Federal and State (self-file) Additional cost for the efile direct add-on service.

About Halfpricesoft.com: Halfpricesoft.com is a leading provider of affordable, easy-to-use payroll and tax compliance software for businesses, accountants, and financial professionals. Its solutions are designed to simplify complex reporting, improve accuracy, and eliminate recurring software costs.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aca-march-deadline-nears-ez1095-xml-import-and-new-direct-e-file-add-on-deliver-fast-compliant-filing-302694218.html

SOURCE Halfpricesoft.com

Market Opportunity
Acala Token Logo
Acala Token Price(ACA)
$0.0006735
$0.0006735$0.0006735
+1.75%
USD
Acala Token (ACA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09